Bioxytran Stock

Bioxytran Current Liabilities

The Current Liabilities of Bioxytran (BIXT) as of Aug 15, 2026 is 3.28 M USD. In the previous year, Current Liabilities was 2.27 M USD — a change of 44.52% (higher).

Current Liabilities

3.28 MUSD

YoY

44.52%

Last updated:

Current Liabilities of Bioxytran is 2026 3.28 M USD. Current Liabilities of Bioxytran was 2025 2.27 M USD. It decreases by 44.52% higher compared to the previous year.
Access this data via the Eulerpool API

Bioxytran Stock analysis

What does Bioxytran do? Bioxytran Inc. is a US-based company specialized in the development of medical therapies based on the use of oxygen transport molecules. The company's patented platform technology focuses on the development of new innovative therapies for treating central nervous system disorders, cardiovascular diseases, and cancer treatment. The company was founded in 2014 by a group of scientists and entrepreneurs aiming to create a transformative medical product that improves oxygen transport in the body and enables the treatment of severe diseases. Bioxytran's platform is based on the use of perfluorocarbon compounds (PFCs) that have a strong affinity for oxygen and can bind and transport it in the blood. The company's business model is centered on the development and commercialization of new therapies to treat diseases such as stroke, heart attack, cancer, and even COVID-19. By improving oxygen transport in the body, Bioxytran aims to enhance the effectiveness of medical treatments and create new therapeutic possibilities. The company's focus areas include stroke treatment, where they have developed a technology that allows direct oxygen transport to the affected brain tissue, minimizing neural damage and enabling faster recovery. They have also developed a new type of heart attack treatment that aims to improve blood flow and eliminate oxygen deficiency in the heart, as well as another therapy option for patients suffering from acute heart attacks. In the field of cancer treatment, Bioxytran has a promising therapy in the pipeline based on PFCs that can selectively target cancer cells, potentially making chemotherapy more effective and patient-friendly. Overall, Bioxytran's goal is to develop medical therapies that have the potential to revolutionize the treatment of severe diseases. They offer a range of products and approaches that have the potential to improve the lives of many patients. In summary, Bioxytran Inc. is an emerging company in the field of medical therapies, driven by innovation and technological expertise. Their focus on developing high-potential products that improve oxygen transport in the body facilitates the treatment of severe diseases. With their various divisions and products, Bioxytran is able to address a broad spectrum of medical needs. Bioxytran is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioxytran stock

Current Liabilities of Bioxytran is 3.28 M USD in 2026.

Current Liabilities of Bioxytran changed from 2.27 M USD to 3.28 M USD, representing a 44.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Bioxytran since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Bioxytran historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Bioxytran

All Key Metrics — Bioxytran